Services on Demand
Article
Indicators
Health indicators
Cited by SciELO
Access statistics
Related links
Bookmark
Revista de Saúde Pública
Print version ISSN 0034-8910
Abstract
LINDNER, Leandro Mendonça; MARASCIULO, Antonio Carlos; FARIAS, Mareni Rocha and GROHS, Geder Evandro Motta. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev. Saúde Pública [online]. 2009, vol.43, suppl.1, pp. 62-69. ISSN 0034-8910.
OBJECTIVE: To assess the cost-utility of first and second-generation antipsychotics for treatment of schizophrenia. METHODS: A five-year Markov model was constructed based on a survey of the records of patients seen in 2006 at a psychosocial care center in the municipality of Florianopolis, Southern Brazil. Costs were evaluated from the perspective of the Sistema Único de Saúde (SUS - Unified Healthcare System). Utility was measured in quality-adjusted life years obtained in the literature. RESULTS: The Markov model indicated risperidone and haloperidol utilization before olanzapine as the most cost-effective alternatives. CONCLUSIONS: Antipsychotic agents haloperidol and risperidone are more cost-effective than olanzapine. Strategies prioritizing the use of antipsychotics with better cost-effectiveness could optimize resource allocation without necessarily compromising the health of patients treated through the Sistema Único de Saúde.
Keywords : Antipsychotic Agents; Schizophrenia; Health Care Costs Quality-Adjusted Life Years; Single Health System; Cost-Effectiveness Evaluation.









